Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets Other stock markets 01:54:12 01/07/2026 HKT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-93.33%

15/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
13/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73K 74.44K 69.41K 63.76K 121K 8.16M 122K 818K 320K 4.08M 322K 315K 13.51M	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	3.92M 3.4M 3.17M 2.91M 5.51M 373M 5.57M 37.38M 14.61M 186M 14.71M 14.38M 617M	EV / Sales 2021	93,978,853,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
13/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/03/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/03/23	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/11/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
13/08/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/05/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
12/05/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/03/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/03/22	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/11/21	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

07/12/23	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/03/23	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/03/23	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/12/22	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/11/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Stock

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news : Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

Current year	0		0.01
1 year	0		0.01
3 years	0		0.06
5 years	0		12.5
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/12/21	Texas Mdi, Inc.	Don	Company	2,000,000	1.0332%
27/12/21	Sean Berrier	Don	Executive/Senior Manager	2,000,000	1.0332%
27/8/21	Henry Punzi	Other	Director	125,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.08	-
Net income	-2.87M -2.49M -2.32M -2.13M -4.03M -273M -4.08M -27.37M -10.7M -136M -10.77M -10.53M -452M	-1.79M -1.56M -1.45M -1.33M -2.52M -171M -2.55M -17.13M -6.7M -85.34M -6.74M -6.59M -283M
Net Debt	1.79M 1.56M 1.45M 1.33M 2.52M 171M 2.55M 17.11M 6.69M 85.26M 6.73M 6.59M 282M	3.83M 3.33M 3.1M 2.85M 5.39M 364M 5.45M 36.56M 14.29M 182M 14.39M 14.07M 604M

3 months	-98.33%
6 months	-98.33%
Current year	-93.33%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	-.--%	-.--%	-98.65%	-99.88%	1.9K
YUNNAN BAIYAO GROUP CO.,LTD	-1.55%	-1.03%	-9.29%	-6.00%	13.66B
BEIJING TONGRENTANG CO., LTD	-2.68%	-1.61%	-32.44%	-54.39%	5.24B
DONG-E-E-JIAO CO., LTD.	-0.64%	+4.33%	+5.28%	+8.07%	5.16B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-2.08%	-0.96%	+0.86%	-33.25%	4.16B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.35%	+2.39%	-9.47%	-4.11%	3.75B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	-0.61%	-0.87%	-3.39%	+4.67%	3.6B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.82%	-0.06%	-4.96%	+12.93%	3.51B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.89%	+0.26%	-14.66%	-23.12%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-1.53%	0.00%	-4.10%	+49.80%	1.9B
Average	-1.22%	-2.13%	-17.08%	-14.53%	4.34B
Weighted average by Cap.	-1.44%	-2.68%	-8.63%	-8.72%